In conclusion, CD4+ T cells play an important role in anti-tumor immunity, and dynamic monitoring of CD4+ T cells during immunotherapy could help to evaluate the prognosis of patients and screen for possible patient groups that might particularly benefit. This evidence concerns the gene CD4 and neoplasm.